Concomitant medications
®
At randomisation, on average, individuals in both arms were treated with one glucose-lowering agent. There were 14 recorded medications for the liraglutide arm; all patients were treated with metformin (13/13), and one was additionally treated with insulin (Tresiba®/degludec insulin). For the placebo arm, there were 20 recorded medications, 100% (14/14) of patients were treated with metformin, 14.3% (2/14) were on dapagliflozin, 7.1% (1/14) were treated with either gliclazide, Humulin I®, Insulutard® or Victoza®. During follow-up, 6 new glucose-lowering medications were used in the liraglutide group and 3 new glucose-lowering medications in the placebo group. For the liraglutide group participants were started on: 2 metformin, 2 empagliflozin, 1 canagliflozin, 1 semaglutide. For the placebo arm participants were started on: 1 metformin, 2 dapagliflozin (Supplementary Table 